कृपया अन्य खोज का प्रयास करें
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer’s, as well as under preclinical studies for the treatment of Parkinson’s disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer’s disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Jeremy M. Shefner | - | - | Chair of Scientific Advisory Board |
Jinsy Andrews | - | - | Scientific Advisory Board Member |
Orla Hardiman | - | - | Scientific Advisory Board Member |
Jeffery Rosenfeld | - | - | Scientific Advisory Board Member |
Merit Cudkowicz | 58 | - | Scientific Advisory Board Member |
Cary John Claiborne | 62 | 2021 | Independent External Director |
Mark Wayne Leuchtenberger | 55 | 2021 | Independent Chairman of the Board |
Caren Deardorf | 57 | 2021 | Independent Director |
Revital Mandil-Levin | 49 | 2022 | Director |
Christine A. Pellizzari | 55 | 2021 | Independent External Director |
Alon Ben-Noon | 45 | 2016 | Co-Founder, CEO & Director |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है